Research programme: TGF-beta RI kinase inhibitors - Scios
Alternative Names: SX-007; TGF-beta RI kinase inhibitors; TGF-beta RI kinase inhibitors research programme - SciosLatest Information Update: 16 Jul 2016
At a glance
- Originator Scios
- Class
- Mechanism of Action Transforming growth factor beta1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glioblastoma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Glioblastoma in USA
- 09 May 2005 Preclinical trials in Glioblastoma in USA (unspecified route)